Concepedia

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

Scott A. Laurie, Ashish Gupta, Quincy S. Chu, Christopher W. Lee, W. Morzycki, Ronald Feld, Alison H. Foo, Jean M. Seely, John R. Goffin, Francis Laberge,

Journal of Thoracic Oncology · 2011 · 68 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

, , +9

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold et al. · Journal of Clinical Oncology · 2005 · 621 citations · Full text

, , +14

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

Luigi Strizzi, Alfonso Catalano, Giovina Vianale et al. · The Journal of Pathology · 2001 · 345 citations

, , +17